WO2009082819A8 - Nouveaux dérivés de lupane - Google Patents

Nouveaux dérivés de lupane Download PDF

Info

Publication number
WO2009082819A8
WO2009082819A8 PCT/CA2008/002291 CA2008002291W WO2009082819A8 WO 2009082819 A8 WO2009082819 A8 WO 2009082819A8 CA 2008002291 W CA2008002291 W CA 2008002291W WO 2009082819 A8 WO2009082819 A8 WO 2009082819A8
Authority
WO
WIPO (PCT)
Prior art keywords
formula
treatment
pharmaceutically acceptable
relates
novel
Prior art date
Application number
PCT/CA2008/002291
Other languages
English (en)
Other versions
WO2009082819A1 (fr
Inventor
Christophe Moinet
Liliane Halab
Nathalie Turcotte
Monica Bubenik
Marc Courchesne
Carl Poisson
Oswy Z. Pereira
Paul Nguyen-Ba
Bingcan Liu
Nathalie Chauret
Caroline Cadilhac
Laval Chan Chun Kong
Original Assignee
Virochem Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virochem Pharma Inc. filed Critical Virochem Pharma Inc.
Priority to AU2008342537A priority Critical patent/AU2008342537A1/en
Priority to CA2711424A priority patent/CA2711424A1/fr
Priority to MX2010007375A priority patent/MX2010007375A/es
Priority to EP08869088A priority patent/EP2250185A4/fr
Priority to JP2010540997A priority patent/JP2011508748A/ja
Priority to CN2008801275273A priority patent/CN101981047A/zh
Publication of WO2009082819A1 publication Critical patent/WO2009082819A1/fr
Publication of WO2009082819A8 publication Critical patent/WO2009082819A8/fr
Priority to US12/830,293 priority patent/US8269026B2/en
Priority to US12/830,294 priority patent/US8431556B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés de 21-céto triterpènes de formule (I) : R1, X, et Y étant tels que définis dans la description, et des sels et des solvates de ceux-ci pharmaceutiquement acceptables. Ces composés présentent une activité anti-VIH significative. L'invention concerne également des procédés de prévention ou de traitement des infections par le VIH par administration de quantités thérapeutiquement efficaces d'un composé de formule (I), ou d'un sel ou solvate pharmaceutiquement acceptable de celui-ci, à un sujet ayant besoin d'un tel traitement.
PCT/CA2008/002291 2008-01-03 2008-12-23 Nouveaux dérivés de lupane WO2009082819A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2008342537A AU2008342537A1 (en) 2008-01-03 2008-12-23 Novel lupane derivatives
CA2711424A CA2711424A1 (fr) 2008-01-03 2008-12-23 Nouveaux derives de lupane
MX2010007375A MX2010007375A (es) 2008-01-03 2008-12-23 Nuevos derivados de lupano.
EP08869088A EP2250185A4 (fr) 2008-01-03 2008-12-23 Nouveaux dérivés de lupane
JP2010540997A JP2011508748A (ja) 2008-01-03 2008-12-23 新規のルパン誘導体
CN2008801275273A CN101981047A (zh) 2008-01-03 2008-12-23 新的羽扇烷衍生物
US12/830,293 US8269026B2 (en) 2008-01-03 2010-07-03 Lupane derivatives useful for treating HIV
US12/830,294 US8431556B2 (en) 2008-03-26 2010-07-03 C-21-keto lupane derivatives preparation and use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1875908P 2008-01-03 2008-01-03
US61/018,759 2008-01-03
US3966008P 2008-03-26 2008-03-26
US61/039,660 2008-03-26

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/830,293 Continuation US8269026B2 (en) 2008-01-03 2010-07-03 Lupane derivatives useful for treating HIV
US12/830,294 Continuation US8431556B2 (en) 2008-03-26 2010-07-03 C-21-keto lupane derivatives preparation and use thereof

Publications (2)

Publication Number Publication Date
WO2009082819A1 WO2009082819A1 (fr) 2009-07-09
WO2009082819A8 true WO2009082819A8 (fr) 2009-10-22

Family

ID=40823729

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2008/002291 WO2009082819A1 (fr) 2008-01-03 2008-12-23 Nouveaux dérivés de lupane

Country Status (7)

Country Link
EP (1) EP2250185A4 (fr)
JP (1) JP2011508748A (fr)
CN (1) CN101981047A (fr)
AU (1) AU2008342537A1 (fr)
CA (1) CA2711424A1 (fr)
MX (1) MX2010007375A (fr)
WO (1) WO2009082819A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102670628B (zh) 2008-01-25 2015-11-25 奇默里克斯公司 治疗病毒感染的方法
US8624023B2 (en) * 2008-12-11 2014-01-07 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
US8802727B2 (en) 2009-07-14 2014-08-12 Hetero Research Foundation, Hetero Drugs Limited Pharmaceutically acceptable salts of betulinic acid derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
TR201807704T4 (tr) 2010-01-27 2018-06-21 Viiv Healthcare Co Anti-viral tedavi.
BR112012019762A2 (pt) * 2010-02-11 2016-02-23 Glaxosmithkline Llc composto, composição, e, método para tratar uma doença.
DK2534150T3 (en) 2010-02-12 2017-06-12 Chimerix Inc METHODS OF TREATING VIRUS INFECTION
WO2011139709A2 (fr) 2010-04-26 2011-11-10 Chimerix, Inc. Méthodes de traitement d'infections rétrovirales et régimes posologiques associés
AU2012352129B2 (en) * 2011-12-14 2016-02-04 Glaxosmithkline Llc Propenoate derivatives of betulin
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
CN103242413B (zh) 2012-02-08 2015-08-26 江西青峰药业有限公司 Lupane三萜系衍生物及其药学用途
US8906889B2 (en) * 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
MX2015007563A (es) 2012-12-14 2015-10-14 Glaxosmithkline Llc Composiciones farmaceuticas.
US9637516B2 (en) 2012-12-31 2017-05-02 Hetero Research Foundation Betulinic acid proline derivatives as HIV inhibitors
US20170129916A1 (en) 2014-06-26 2017-05-11 Hetero Research Foundation Novel betulinic proline imidazole derivatives as hiv inhibitors
AU2015323321A1 (en) 2014-09-26 2017-04-13 Glaxosmithkline Intellectual Property (No.2) Limited Long acting pharmaceutical compositions
US9969767B2 (en) * 2014-11-14 2018-05-15 VIIV Healthcare UK (No.5) Limited Oxolupene derivatives
MA40886B1 (fr) * 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
WO2016147099A2 (fr) * 2015-03-16 2016-09-22 Hetero Research Foundation Nouveaux triterpénone c-3 avec des dérivés amide c-28 servant d'inhibiteurs de vih
US10669305B2 (en) * 2015-10-13 2020-06-02 Hetero Labs Limited C-3 novel triterpenone with C-28 urea derivatives as HIV inhibitors
EP3405474A1 (fr) * 2016-01-20 2018-11-28 Glaxosmithkline Intellectual Property (No. 2) Limited Dérivés amine de lupanes ayant une activité inhibitrice de la maturation du vih
WO2018025247A1 (fr) * 2016-08-05 2018-02-08 Hetero Labs Limited Nouvelle triterpénone en c-3 avec des dérivés de diamide en c-28 en tant qu'inhibiteurs du vih
WO2018029604A1 (fr) * 2016-08-08 2018-02-15 Hetero Labs Limited Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-17 en tant qu'inhibiteurs du vih
WO2018029610A1 (fr) * 2016-08-09 2018-02-15 Hetero Labs Limited Nouvelle triterpénone en c-3 avec des dérivés de n-amide en c-17 en tant qu'inhibiteurs du vih
WO2018065930A1 (fr) * 2016-10-05 2018-04-12 Hetero Labs Limited Triterpénone en c-3 avec des dérivés amides inversés en c-17 en tant qu'inhibiteurs du vih
WO2018069857A1 (fr) * 2016-10-12 2018-04-19 Hetero Labs Limited Nouvelle triterpénone en c-3 à dérivés hétérocycliques d'amide inverse en c-17 utilisés comme inhibiteurs du vih
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
EP1292562A1 (fr) * 2000-05-23 2003-03-19 Univerzita palackeho V Olomouci Derives triterpenoides
US20060019934A1 (en) * 2004-05-20 2006-01-26 Saxena Brij B Anti-HIV-1 activity of betulinol derivatives
TW200628161A (en) * 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof

Also Published As

Publication number Publication date
MX2010007375A (es) 2010-09-30
EP2250185A1 (fr) 2010-11-17
JP2011508748A (ja) 2011-03-17
CA2711424A1 (fr) 2009-07-09
AU2008342537A1 (en) 2009-07-09
EP2250185A4 (fr) 2011-11-16
WO2009082819A1 (fr) 2009-07-09
CN101981047A (zh) 2011-02-23

Similar Documents

Publication Publication Date Title
WO2009082819A8 (fr) Nouveaux dérivés de lupane
WO2009082818A8 (fr) Préparation de nouveaux dérivés de c-21-céto lupane et leur utilisation
PH12017501429A1 (en) Derivatives of betulin
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
WO2017123884A8 (fr) Composés hétérocycliques utilisés comme inhibiteurs du vrs
WO2020257549A3 (fr) Composés pour le traitement de maladies pd-l1
WO2012142093A3 (fr) Dérivés nucléosides à substitution 2'-cyano et leurs procédés d'utilisation pour traitement de maladies virales
TN2015000121A1 (en) Gdf-8 inhibitors
EP4316591A3 (fr) Oxystérols et leurs procédés d'utilisation
WO2012018534A3 (fr) Composés de biphénylène substitué et procédés d'utilisation desdits composés pour le traitement de maladies virales
TW200728307A (en) Novel spirochromanone derivatives
WO2008154642A3 (fr) Agents antibactériens
WO2008012635A3 (fr) Dérivés d'amines utiles en tant qu'agents anticancéreux
WO2009155121A3 (fr) Inhibiteurs de la pi3 kinase
WO2007135527A3 (fr) Composés de benzimidazolyle
WO2009146555A8 (fr) Inhibiteurs de l'intégrase du vih, issus de la pyridoxine
WO2011027249A3 (fr) Dérivés de benzimidazole
WO2012125926A3 (fr) Dérivés tétracycliques de xanthène et leurs méthodes d'utilisation en vue du traitement de maladies virales
WO2011044501A3 (fr) Analogues d'aminoglycoside antibactériens
EP2639229A3 (fr) Dérivé de thiazole et son utilisation en tant qu'inhibiteur VAP-1
TN2019000170A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
WO2010132757A3 (fr) Analogues d'aminoglycoside antibactériens
WO2014172188A3 (fr) Composés dérivés de 4-pyridone et leurs utilisations en tant qu'inhibiteurs de la vih intégrase
CA2862755A1 (fr) Composes antiviraux avec une fraction dibenzooxaheterocycle
NZ600912A (en) Topical use of hydroxytyrosol and derivatives for the prevention of hiv infection

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880127527.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08869088

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2711424

Country of ref document: CA

Ref document number: 2010540997

Country of ref document: JP

Ref document number: MX/A/2010/007375

Country of ref document: MX

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2574/KOLNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008342537

Country of ref document: AU

Ref document number: 586814

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2008869088

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: 2008342537

Country of ref document: AU

Date of ref document: 20081223

Kind code of ref document: A